IMS launches MIDAS Global Biologics

IMS Health, the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, announced the launch of IMS MIDAS Global Biologics, a powerful offering that enables the company's clients to make more confident decisions as they assess opportunities in the fast-growing, US$ 120 billion worldwide biologics market. MIDAS Global Biologics provides an unprecedented understanding of biologics at both the molecule and product level for deeper insights into market size, performance and changing biologics usage in more than 70 countries.

Comments

Popular posts from this blog

Trump wants more mental health care; Alabama says it's trying

Smokefree Mumbai campaign responds to recent study by BCM, Houston that claims smoking create stronger memory